Recursion Pharmaceuticals Inc. stocks have been trading up by 9.8 percent after groundbreaking AI-driven drug discovery progress boosted investor optimism.
Live Update At 17:04:04 EDT: On Thursday, June 04, 2026 Recursion Pharmaceuticals Inc. stock [NASDAQ: RXRX] is trending up by 9.8%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
RXRX has been quietly grinding higher on the chart. In late May, the stock was closing around $2.85–$3.01. By 2026/06/04, RXRX closed at $3.80 after hitting an intraday high of $4.04. That is a meaningful multi‑week trend for short‑term traders watching momentum.
Intraday action shows RXRX holding gains. After the morning push to just over $4, the stock mostly traded between $3.80 and $3.90 with tight five‑minute candles. That tells traders there was real demand supporting the move instead of a quick spike and fade.
Fundamentally, RXRX remains an early‑stage, high‑burn biotech wrapped around an AI platform. Quarterly revenue is only about $6.5M, and full‑year revenue stands near $74.7M, but the company carries an enterprise value around $1.26B. That means RXRX trades at roughly 28.8x sales, classic speculative territory.
Margins are deeply negative, and returns on assets and equity are firmly in the red, as expected for a platform biotech. The positive here is balance‑sheet strength: RXRX holds roughly $654M in cash and short‑term investments, a current ratio of 5.5, and very low debt. For traders, that long runway reduces near‑term financing shock risk and lets the chart trade more on headlines and sentiment than survival fears.
Why Traders Are Watching RXRX Right Now
RXRX stepped into the spotlight with its Q1 2026 report. The company posted an EPS loss of -$0.22 versus Wall Street expectations of -$0.26. In plain English, traders were braced for a bigger hit, and RXRX lost less than feared. On top of that, revenue for the quarter came in “extremely strong” versus consensus, giving the bull side real numbers to lean on instead of just hype.
More important for a story like RXRX, management repeated that its cash runway extends into early 2028. Cash flow data backs that up: the quarter saw about -$81.1M in operating cash flow and -$81.4M in free cash flow, but the company still ended with roughly $665M in cash. Combine that with low leverage, and RXRX has room to keep funding its AI‑driven pipeline without rushing back to the market every few months.
Q1 also brought substance on the science side. RXRX highlighted positive early clinical data in several oncology programs and strong Phase 2 signals in familial adenomatous polyposis. Progress in partnered AI discovery work adds another support beam to the story. For traders, this is what you want to see: not just a fancy AI pitch, but data that suggests the platform may be turning into real drugs.
Morgan Stanley’s price‑target move to $5.50 from $5.00 lines up with that narrative. It is not a “back up the truck” call — Equal Weight keeps expectations grounded — but for RXRX, any upward revision from a major bank is a psychological tailwind. Add in the Altitude Lab ecosystem news and new RSU grants for 33 hires, and traders see a company still building, still hiring, and still central to its local biotech hub. That supports the recent drift higher in RXRX shares.
More Breaking News
- Opendoor Technologies Stock Slips As Losses Deepen And Targets Shift
- OPTU Stock Slumps As Weak Financials Weigh On Momentum
- GXAI Stock Sees Volatile Spike As Traders Circle Key Levels
- MRVL Stock Rockets As AI Demand Fuels Record Growth
Conclusion
RXRX is a classic high‑risk biotech chart, but the recent mix of news tilts the balance toward cautious optimism. The stock has pushed from the high‑$2s to around $3.80 over the past couple of weeks, and the intraday tape shows controlled consolidation rather than panic selling. Earnings came in better than feared on both the top and bottom lines, and the company backed that up with a runway into early 2028 and real progress across oncology and AI‑driven programs.
Traders still need to respect the downside. RXRX’s margins are deeply negative, cash burn is heavy, and any bad clinical readout can slam the chart. Dilution risk is not gone either, especially with inducement RSUs adding to the share count over time. The elevated price‑to‑sales multiple means RXRX is priced as a story stock, not a value play.
For active traders, the key is to treat RXRX as a momentum and catalyst vehicle. Watch how price reacts around levels like $3.50 support and the recent $4.00 area, and pair that with upcoming data or partnership headlines. As millionaire penny stock trader and teacher Tim Sykes says, “Preparation plus patience leads to big profits.” As Tim Sykes loves to say, “Patterns repeat, traders don’t.” RXRX is giving the market a cleaner pattern now — better numbers, a strong cash cushion, and a rising price target — but disciplined trading, tight risk, and fast cuts on weakness still matter more than any single biotech story.
This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.
Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:
- Penny Stocks Trading Guide
- Best Penny Stocks Under $1 to Buy Today
- Top 8 Penny Stocks to Watch on Robinhood
Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:
Leave a reply